Neville, Jr.; David M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Neville, Jr.; David M..The latest application filed is for "immunomodulation by anti-cd3 immunotoxins to treat cancers not uniformly bearing surface cd3".

Company Profile

0.16.8

Neville, Jr.; David M. - Bethesda MD US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Fold-back diabody diphtheria toxin immunotoxin and methods of use Grant 9,364,557 - Neville, Jr. , et al. June 14, 2	2016-06-14
Immunomodulation By Anti-cd3 Immunotoxins To Treat Cancers Not Uniformly Bearing Surface Cd3 App 20150166660 - Neville, JR.; David M.	2015-06-18
Immunotoxin fusion proteins and means for expression thereof Grant 8,987,426 - Neville, Jr. , et al. March 24, 2	2015-03-24
Methods for expression and purification of immunotoxins Grant 8,921,097 - Neville, Jr. , et al. December 30, 2	2014-12-30
Methods For Expression And Purification Of Immunotoxins App 20130217861 - Neville, JR.; David M. ; et al.	2013-08-22
Immunotoxin Fusion Proteins And Means For Expression Thereof App 20130211049 - Neville, JR.; David M. ; et al.	2013-08-15
Immunotoxin fusion proteins and means for expression thereof Grant 8,217,158 - Neville, Jr. , et al. July 10, 2	2012-07-10
Fold-back Diabody Diphtheria Toxin Immunotoxin And Methods Of Use App 20110189209 - Neville, JR.; David M. ; et al.	2011-08-04
Immunotoxin Fusion Proteins And Means For Expression Thereof App 20110086416 - Neville, Jr.; David M. ; et al.	2011-04-14
Immunotoxin fusion proteins and means for expression thereof Grant 7,696,338 - Neville, Jr. , et al. April 13, 2	2010-04-13
Immunotoxin with in vivo T cell suppressant activity and methods of use Grant 7,517,527 - Neville, Jr. , et al. April 14, 2	2009-04-14
Immunotoxin With In Vivo T Cell Suppressant Activity And Methods Of Use App 20030157093 - NEVILLE, JR., DAVID M. ; et al.	2003-08-21
Immunotoxin with in-vivo T cell suppressant activity Grant 5,167,956 - Neville, Jr. , et al. December 1, 1	1992-12-01
Protein crosslinking reagents cleavable within acidified intracellular vesicles Grant 5,066,490 - Neville, Jr. , et al. November 19, 1	1991-11-19
Inactivating protein synthesis by incubating anti-Thy 1.1-ricin a chain monoclonal antibody hybrids with target protein cells Grant 4,520,011 - Neville, Jr. , et al. May 28, 1	1985-05-28
Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates Grant 4,520,226 - Neville, Jr. , et al. May 28, 1	1985-05-28
Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease Grant 4,440,747 - Neville Jr. , et al. April 3, 1	1984-04-03
Mannose-6-phosphate-low density protein reagent effective against hypercholesterolemia Grant 4,397,843 - Neville, Jr. , et al. August 9, 1	1983-08-09
Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant Grant 4,359,457 - Neville, Jr. , et al. November 16, 1	1982-11-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.